Gout Study Group: Update on hyperuricemia and gout

Terkeltaub, Robert; Zelman, David; Scavulli, John F.; Pérez-Ruiz, Fernando; Lioté, Frédéric

doi:10.1016/j.jbspin.2009.05.006

Cited by 28 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nonsteroidal anti-inflammatory drugs or intraarticular corticosteroid injections are often used for the painful attack of acute gouty arthritis. 8 The pharmacologic management of gout remains difficult, especially in geriatric patients, because of the risk of gastrointestinal and nephrotoxic side effects. Surgical enucleation is advised for tophi covered by ulcerated and infected skin.…”

Section: Historical Perspectivementioning

confidence: 99%

Different Surgical Approaches to Treat Chronic Tophaceous Gout in the Hand: Our Experience

Tripoli

Falcone

Mossuto

et al. 2010

Techniques in Hand &Amp; Upper Extremity Surgery

View full text Add to dashboard Cite

Chronic tophaceous gout is a disabling erosive arthritis characterized by an elevated serum urate concentration, recurrent attacks of arthritis, and deposits of monosodium urate crystals in synovial fluids. Tophi, ulcerations of the overlying skin, and fissures of the interarticular cartilage may occur in advanced stages, combined with deformities of the joints and decreased active joint flexion and extension. Although the timely use of allopurinol is associated with a decrease in the frequency of deposits of the tophaceous substance, however, surgical management is necessary to restore and improve the cosmesis and joint function, to alleviate symptomatic discomfort, and to reduce the risk of infection when the overlying skin becomes ulcerated. The authors present their experience in the surgical management of the chronic tophaceous gout in the hand.

show abstract

Section: Historical Perspectivementioning

confidence: 99%

Different Surgical Approaches to Treat Chronic Tophaceous Gout in the Hand: Our Experience

Tripoli

Falcone

Mossuto

et al. 2010

Techniques in Hand &Amp; Upper Extremity Surgery

View full text Add to dashboard Cite

show abstract

“…NSAIDs are more commonly used in the US and Northern Europe, with colchicine used in France and some countries of southern Europe [15]. Colchicine and low-dose NSAIDs are also used as prophylactic treatment to prevent flares after the initiation of urate-lowering therapy (ULT) [11,14].…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics considerations for gout treatments

Richette

Frazier

Bardin

2014

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

Colchicine is a drug with a narrow therapeutic-toxicity window. Co-prescription with strong CYP3A4 or P-glycoprotein inhibitors can greatly modify its pharmacokinetics and is to be avoided. Elimination of canakinumab mainly occurs via intracellular catabolism, following receptor mediator endocytosis. Canakinumab appears to be a good alternative for patients with contraindications to colchicine, NSAIDs and corticosteroids. For patients with renal impairment, some authors recommend that the allopurinol maximum dosage should be adjusted to creatinine clearance. If the urate target cannot be achieved, the therapy should be switched to febuxostat, which is appropriate with mild-to-moderate renal failure. Anti-pegloticase antibodies affect the pharmacokinetics of the drug because they increase its clearance, with loss of pegloticase activity.

show abstract

“…The incidence of gout is on the rise, and gout recently passed rheumatoid arthritis to become the most common inflammatory arthritis in the United States, affecting some three million individuals. 1,2 In gout, the presence of high levels of serum urate (hyperuricemia) results in the precipitation of monosodium urate crystals, which then activate the complement cascade, macrophages and neutrophils to stimulate episodic and often severe inflammatory responses. 3,4 The deposition of large masses of sodium urate crystals in the synovium, surrounded by coronas of inflammatory cells (tophaceous gout), causes tissue and joint damage and chronic pain.…”

Section: Introductionmentioning

confidence: 99%

Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia

Beara-Lasić

Pillinger²,

Goldfarb³

2010

IJNRD

View full text Add to dashboard Cite

Gout recently passed rheumatoid arthritis to become the most common inflammatory arthritis in the United States (US). However, epidemiologic studies indicate that the quality of gout management is suboptimal owing to both patient and physician issues. Only three options for urate-lowering therapy are currently available in the US: allopurinol, probenecid, and recently, febuxostat. Probenecid is generally safe except for the occurrence of urolithiasis, but is only effective for the subset of patients with better kidney function. Allopurinol use is limited due to its side effects, potential toxicity of uncertain magnitude in patients with renal disease, and failure to achieve targeted serum urate levels. In part this failure may be due to the necessity for it to be titrated for optimal therapeutic effect. Febuxostat is a new medication that may offer several advantages and can be given as an alternative to allopurinol. We review the basic biology and clinical performance of febuxostat, and consider the potential utility of this agent in comparison to the older, better-established gout therapeutics.

show abstract

Gout Study Group: Update on hyperuricemia and gout

Cited by 28 publications

References 10 publications

Different Surgical Approaches to Treat Chronic Tophaceous Gout in the Hand: Our Experience

Different Surgical Approaches to Treat Chronic Tophaceous Gout in the Hand: Our Experience

Pharmacokinetics considerations for gout treatments

Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia

Contact Info

Product

Resources

About